Solid tumor/s, Cancer
HOWLWerewolf TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for WTX-124 +/- pembrolizumab (IL-2 INDUKINE™) in Solid tumor/s, Cancer. The expected timing is based on the latest available company guidance and may change.
07/31/26:- WTX-124 clinical trial data update expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.